Piano Marianne E F, Simmers Anita J
School of Health Sciences, University of Surrey, Guildford, UK.
Department of Vision Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Ther Adv Ophthalmol. 2019 Jun 19;11:2515841419857379. doi: 10.1177/2515841419857379. eCollection 2019 Jan-Dec.
In recent years, media coverage has demonstrated instances in which families of children aged 7 and older, newly diagnosed with strabismic and/or anisometropic amblyopia through community eyecare services, were told it was 'too late' for their child to effectively respond to conventional amblyopia treatment (occlusion or atropine penalisation). Formal guidance pertaining to binocular vision anomalies from eyecare professional bodies does not specifically make reference to a child's age, beyond stating the importance of early diagnosis and treatment of strabismus/amblyopia. However, there have been many changes in the way we view the recovery period for amblyopia, and it is well demonstrated both within literature and clinical practice that conventional treatment can improve amblyopic eye visual acuity in children beyond the age of 7 years. The occurrence of these media described cases within the community eyecare sphere would suggest it is worthwhile revisiting the literature on the subject of amblyopia treatment in older children (aged 7+ years), to address misconceptions and place in the spotlight current considerations facing clinicians when treating newly diagnosed amblyopia within this age group. This perspective review provides an evidence-based update covering the various considerations associated with treatment of amblyopia in older children, along with recent amblyopia treatment advances that could have an impact on treatment prospects for this patient group. Considerations include the risks, benefits and efficacy of treating newly diagnosed amblyopia in older children, monitoring density of suppression to mitigate intractable diplopia risk, and recent findings regarding binocular treatments for amblyopia.
近年来,媒体报道了一些案例,通过社区眼保健服务新诊断为斜视性和/或屈光参差性弱视的7岁及以上儿童的家庭被告知,他们的孩子对传统弱视治疗(遮盖或阿托品压抑疗法)做出有效反应“为时已晚”。眼保健专业机构关于双眼视觉异常的正式指南除了强调斜视/弱视早期诊断和治疗的重要性外,并未特别提及儿童的年龄。然而,我们对弱视恢复期的看法已经发生了许多变化,文献和临床实践都充分表明,传统治疗可以提高7岁以上儿童弱视眼的视力。社区眼保健领域出现的这些媒体报道的案例表明,有必要重新审视关于大龄儿童(7岁及以上)弱视治疗的文献,以消除误解,并将临床医生在治疗该年龄组新诊断弱视时面临的当前考虑因素置于关注焦点。这篇观点综述提供了基于证据的更新内容,涵盖与大龄儿童弱视治疗相关的各种考虑因素,以及可能影响该患者群体治疗前景的最新弱视治疗进展。考虑因素包括治疗大龄儿童新诊断弱视的风险、益处和疗效,监测抑制密度以降低顽固性复视风险,以及关于弱视双眼治疗的最新研究结果。